

## Special Issue

# The Effect of Influenza Vaccination on Chronic Disease

### Message from the Guest Editors

The impact of influenza vaccination on reducing the risk of influenza virus infection has been well-documented. In addition to protecting against infection, the vaccine can significantly lower the risk of mortality and other complications associated with the virus, making it highly recommended, especially for high-risk populations such as the elderly, patients with chronic diseases, and healthcare providers. While research has demonstrated other potential benefits of influenza vaccination, detailed clinical data and mechanisms supporting its additional effects among patients with chronic diseases are still lacking. By gaining a deeper understanding of the protective benefits of the influenza vaccine beyond infection prevention, we can further improve the long-term outcomes of patients with chronic diseases. Therefore, we invite you to submit research articles on the effectiveness and potential mechanisms of the influenza vaccine in this population. We welcome the submission of clinical observational studies, randomized control trials, and basic molecular/animal investigations.

---

### Guest Editors

Prof. Dr. Ju-Chi Liu

Dr. Wen-Rui Hao

Dr. Chun-Chao Chen

---

### Deadline for manuscript submissions

closed (31 May 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.4**  
**CiteScore 9.9**  
**Indexed in PubMed**



[mdpi.com/si/185335](https://mdpi.com/si/185335)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).